Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$314.94 -2.4%	$301.17	$205.87 ▼ $333.70	$42.07B	0.23	856,180 shs	1.08 million shs
ARRY Array Technologies	$7.47 -2.2%	$7.07	$3.76 ▼ $12.06	$1.17B	1.74	6.45 million shs	5.00 million shs
ELAN Elanco Animal Health	$14.90 -1.0%	$13.45	$8.02 ▼ $15.78	$7.47B	1.67	5.06 million shs	3.84 million shs
GLPG Galapagos	$30.30 -0.6%	$28.10	$22.36 ▼ $31.23	$2.00B	0.07	252,776 shs	124,742 shs
OPHLF Ono Pharmaceutical	$10.79	$10.47	$9.20 ▼ $16.05	$5.07B	0.49	140 shs	N/A

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-2.39%	-5.12%	+5.48%	+32.46%	+22.18%
ARRY Array Technologies	-2.23%	-3.61%	-3.86%	+75.35%	-24.55%
ELAN Elanco Animal Health	-1.09%	+1.75%	+4.53%	+72.41%	+12.08%
GLPG Galapagos	-0.62%	+5.08%	+6.88%	+26.20%	+13.70%
OPHLF Ono Pharmaceutical	0.00%	+15.65%	+1.78%	-7.78%	-20.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNY Alnylam Pharmaceuticals	4.1837 of 5 stars	2.4	4.0	0.0	4.3	3.4	2.5	0.6
ARRY Array Technologies	3.0583 of 5 stars	3.2	2.0	0.0	0.0	2.1	0.0	3.1
ELAN Elanco Animal Health	1.5099 of 5 stars	1.3	1.0	0.0	0.3	2.0	1.7	1.3
GLPG Galapagos	0.4075 of 5 stars	0.8	4.0	0.0	0.0	1.5	0.0	0.6
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.80	Moderate Buy	$345.70	9.77% Upside
ARRY Array Technologies	2.45	Hold	$8.87	18.72% Upside
ELAN Elanco Animal Health	2.50	Moderate Buy	$15.33	2.94% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-16.39% Downside
OPHLF Ono Pharmaceutical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARRY, ALNY, OPHLF, GLPG, and ELAN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$364.00 ➝ $404.00
7/11/2025	ALNY Alnylam Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$336.00 ➝ $359.00
7/7/2025	ALNY Alnylam Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$328.00 ➝ $384.00
7/2/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $17.00
6/30/2025	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$287.00 ➝ $333.00
6/27/2025	ARRY Array Technologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00
6/26/2025	ALNY Alnylam Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$320.00 ➝ $377.00
6/26/2025	ELAN Elanco Animal Health	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
6/24/2025	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$300.00 ➝ $360.00
6/20/2025	ARRY Array Technologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$8.00 ➝ $9.00
6/20/2025	ARRY Array Technologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$12.00 ➝ $13.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$2.25B	18.27	N/A	N/A	$0.52 per share	605.65
ARRY Array Technologies	$915.81M	1.24	$2.78 per share	2.69	($0.78) per share	-9.58
ELAN Elanco Animal Health	$4.44B	1.67	$2.23 per share	6.67	$12.33 per share	1.21
GLPG Galapagos	$288.19M	6.93	$0.72 per share	41.99	$47.57 per share	0.64
OPHLF Ono Pharmaceutical	$3.20B	1.59	$1.08 per share	10.01	$11.07 per share	0.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	-$278.16M	-$2.09	N/A	353.87	N/A	-11.49%	-510.31%	-6.48%	8/7/2025 (Estimated)
ARRY Array Technologies	-$240.39M	-$1.85	N/A	10.67	0.59	-21.21%	1,227.67%	9.83%	8/14/2025 (Estimated)
ELAN Elanco Animal Health	$338M	$0.74	20.13	16.74	2.94	8.43%	7.54%	3.57%	8/7/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
OPHLF Ono Pharmaceutical	$330.31M	$0.70	15.41	∞	N/A	10.24%	6.20%	4.66%	7/28/2025 (Estimated)

Latest ARRY, ALNY, OPHLF, GLPG, and ELAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ALNY Alnylam Pharmaceuticals	-$0.0538	N/A	N/A	N/A	$633.54 million	N/A
8/7/2025	Q2 2025	ELAN Elanco Animal Health	$0.1989	N/A	N/A	N/A	$1.19 billion	N/A
7/23/2025	Q2 2025	GLPG Galapagos	-$0.34	N/A	N/A	N/A	$80.13 million	N/A
5/7/2025	Q1 2025	ELAN Elanco Animal Health	$0.31	$0.37	+$0.06	$0.14	$1.17 billion	$1.19 billion
5/6/2025	Q1 2025	ARRY Array Technologies	$0.09	$0.13	+$0.04	$0.02	$264.14 million	$302.36 million
5/1/2025	Q1 2025	ALNY Alnylam Pharmaceuticals	-$0.37	-$0.44	-$0.07	-$0.44	$584.32 million	$594.19 million
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARRY Array Technologies	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	8.88	3.04	2.98
ARRY Array Technologies	N/A	2.39	1.93
ELAN Elanco Animal Health	0.68	2.71	1.46
GLPG Galapagos	N/A	7.95	7.86
OPHLF Ono Pharmaceutical	0.13	3.07	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
ARRY Array Technologies	N/A
ELAN Elanco Animal Health	97.48%
GLPG Galapagos	32.46%
OPHLF Ono Pharmaceutical	N/A

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	1.50%
ARRY Array Technologies	0.45%
ELAN Elanco Animal Health	0.89%
GLPG Galapagos	2.91%
OPHLF Ono Pharmaceutical	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,230	130.39 million	128.43 million	Optionable
ARRY Array Technologies	1,021	152.55 million	151.86 million	Optionable
ELAN Elanco Animal Health	9,000	496.65 million	492.23 million	Optionable
GLPG Galapagos	1,310	65.90 million	N/A	Optionable
OPHLF Ono Pharmaceutical	3,853	469.71 million	N/A	Not Optionable

ARRY, ALNY, OPHLF, GLPG, and ELAN Headlines

Recent News About These Companies

Ono Pharmaceutical (OTCMKTS:OPHLF) Stock Passes Above 50-Day Moving Average - Here's What Happened

July 11 at 5:30 AM | marketbeat.com

Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up - Time to Buy?

July 10 at 2:16 PM | marketbeat.com

Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down - Here's Why

June 25, 2025 | marketbeat.com

Pharma company announces it will lay off 83 Boston-area employees

April 30, 2025 | msn.com

Pharmaceutical company to cut 83 Boston-area jobs in downsize

April 28, 2025 | masslive.comM

Ono Pharmaceutical Taps Jorna Therapeutics for RNA-Editing Drug Discovery Partnership

April 21, 2025 | precisionmedicineonline.comP

Ono Pharmaceutical Enhances Governance and Diversity Initiatives

March 24, 2025 | tipranks.com

Ono scoops Ionis' hematology candidate sapablursen for up to $940M

March 13, 2025 | bioworld.comB

Ono earmarks $940m to gain rare blood cancer therapy from Ionis

March 12, 2025 | msn.com

ONO-4915 by Ono Pharmaceutical for Autoimmune Disorders: Likelihood of Approval

January 5, 2025 | pharmaceutical-technology.comP

ONO-4685 by Ono Pharmaceutical for T-Cell Lymphomas: Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Risk adjusted net present value: What is the current valuation of Ono Pharmaceutical’s Vimseltinib?

December 16, 2024 | pharmaceutical-technology.comP

Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area

December 5, 2024 | tmcnet.com

Equillium keeps equilibrium in GVHD after Ono no-go

November 1, 2024 | bioworld.comB

Sanofi enters talks with private equity firm to sell controlling stake in consumer health unit Opella

October 11, 2024 | fiercepharma.comF

Ono, Boehringer add to cancer pipelines with licensing deals

October 10, 2024 | pharmaphorum.comP

Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical

October 7, 2024 | standard-journal.comS

Life-saving cancer drug a boon to patients in Japan, but price prompts debate

October 4, 2024 | mainichi.jpM

Nectar Classic Hybrid Mattress review 2024

September 24, 2024 | fortune.com

The best Plank mattresses of 2024, tested and reviewed

September 24, 2024 | fortune.com

Turbine Achieves Key Milestone in Collaboration with Ono Pharmaceutical

September 12, 2024 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARRY, ALNY, OPHLF, GLPG, and ELAN Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$314.94 -7.70 (-2.39%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$314.32 -0.63 (-0.20%)

As of 07/11/2025 07:47 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Array Technologies NASDAQ:ARRY

$7.47 -0.17 (-2.23%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$7.55 +0.08 (+1.07%)

As of 07/11/2025 07:22 PM Eastern

Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products portfolio includes DuraTrack HZ v3, a single axis tracker; Array STI H250 that delivers a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance energy production. Array Technologies, Inc. was incorporated in 1987 and is headquartered in Albuquerque, New Mexico.

Elanco Animal Health NYSE:ELAN

$14.90 -0.14 (-0.96%)

Closing price 07/11/2025 03:58 PM Eastern

Extended Trading

$14.90 +0.01 (+0.06%)

As of 07/11/2025 07:55 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Galapagos NASDAQ:GLPG

$30.30 -0.19 (-0.62%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$30.29 -0.01 (-0.03%)

As of 07/11/2025 04:04 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Ono Pharmaceutical OTCMKTS:OPHLF

$10.79 0.00 (0.00%)

As of 07/11/2025

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time